metabolic syndrome News
-
FR- Report on night work and atypical working times highlights risks to workers
The Frenc Agency ANSES has been commissioned to assess health risks for workers exposed to atypical working schedules, particularly night work. This expert report highlights proven risks such as sleep disorders and metabolic disorders, and likely risks of carcinogenic nature or cardiovascular disorders and mental health problems among concerned workers. Workers who work at night are ...
-
Aker BioMarine Hires Two Top Scientists to Strengthen its R&D Initiatives
Aker BioMarine, a global biotech innovator and world-leading supplier of krill, announces two new talents on the Human Nutrition team. Katina Handeland, PhD., and Yunpeng Ding, PhD. have both joined Aker BioMarine as Directors for Research & Development (R&D). They will be responsible for research within the company’s human health and nutrition department. “We are thrilled to ...
-
Bisphenol A exposure can increase risk of diabetes and heart attacks
In human fat tissues, bisphenol A (BPA) suppresses levels of a key hormone, adiponectin, that protects people from heart attacks and Type II diabetes. These results implicate BPA as a potential cause of metabolic syndrome, one of the most serious and costly public health problems in the US. Most Americans have levels of BPA within their serum within the range of concentrations sufficient to ...
-
Longeveron Announces Initiation of Phase 2a Clinical Trial of Lomecel-B for the Treatment of Alzheimer’s Disease
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and certain life-threatening conditions, announced today the initiation of its Phase 2a clinical trial evaluating Lomecel-B as a treatment for Alzheimer’s disease (AD). The first patient has consented to participate in the trial and ...
-
Creative Proteomics Lipidomics Platform Boosts Short Chain Fatty Acids Research
Lipidomics, a platform developed by Creative Proteomics, is dedicated to providing cutting-edge mass spectrometry (MS)-based lipidomics services for biomedical research institutions, and biotechnological and pharmaceutical companies. The Lipidomics platform now employs gas chromatography-mass spectrometry (GC-MS) methods to enable fast and accurate qualitative and quantitative analysis of a ...
-
Longeveron Enters into Cooperative Research and Development Agreement with the US Department of Veterans Affairs for its Phase 2 Alzheimer’s Trial
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today a Cooperative Research and Development Agreement (CRADA) with the United States Department of Veterans Affairs (VA) for the addition of a Miami VA clinical site to its ongoing Phase 2 ...
-
Longeveron Announces Publication of Lomecel-B Phase 2b Trial Design in Journal of Frailty and Aging
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and certain life-threatening conditions, announced today publication of the design and rationale from its recently completed Phase 2b aging frailty clinical trial with Lomecel-B in the Journal of Frailty and Aging. This peer-reviewed ...
-
Longeveron Expands Executive Leadership Team; Appoints K. Chris Min, M.D., Ph.D. as Chief Medical Officer
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and other specific life-threatening conditions, announced today the addition of K. Chris Min, M.D., Ph.D. to the Longeveron executive leadership team in the role of Chief Medical Officer (CMO), effective April 4, 2022. Dr. Min will lead global ...
-
Inversago Pharma receives IND clearance for Phase 2 trial of INV-202 in Diabetic Kidney Disease
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, has received FDA clearance of its Investigational New Drug (IND) application for a phase 2 study in Diabetic Kidney Disease (DKD) for INV-202, the Company’s lead program. Inversago scientists identified Diabetic Kidney Disease as the most ...
-
US and Canada partner to invest $21 million for research hubs in developing countries
The National Institutes of Health and other U.S. and Canadian partners are investing $20.9 million dollars over five years to establish seven regional research and training centers in low- and middle-income countries (LMICs). The Global Environmental and Occupational Health (GEOHealth) Hubs will consist of multidisciplinary groups of researchers and partner organizations collaborating on common ...
-
Feldan Therapeutics forms A Scientific Advisory Board and Expands Its Leadership Team
Feldan Therapeutics, a biotechnology company focusing on the development of therapeutics based on the intracellular delivery of proteins and peptides, announces the creation of a scientific advisory board and the appointment of an Acting Vice-President, Drug Development. “I am glad to welcome a group of highly experienced scientists having extensive clinical development and executive ...
-
Alnylam and Regeneron Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
Target knockdown and safety results support continued clinical development Alnylam and Regeneron intend to initiate a Phase 2 study in late 2022 Detailed results to be presented at an upcoming medical congress CAMBRIDGE, Mass. & TARRYTOWN, N.Y.--(BUSINESS WIRE)--Sep. 15, 2022-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Regeneron Pharmaceuticals (Nasdaq: REGN) announced today ...
-
Creative Proteomics Launches Short-Chain Fatty Acid Analysis to Aid Gut Microbiota Research
With over 10 years of experience in advanced multi-omics services, Creative Proteomics has established a metabolomics platform dedicated to providing high-quality, personalized services, and reliable data to support global clients. With this metabolomics platform, the company was able to launch a new set of short-chain fatty acid analysis services. Short-chain fatty acids (SCFA) are organic ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you